Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial

NCT04838301 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT04838301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04838301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 15, 2023
Completion date
March 18, 2027
Enrollment
100 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer dementia, late onset alzheimer disease, neurodegenerative diseases